On August 28, AB&B BIO-TECH-B (02627) showed active performance in late trading with its stock price surging rapidly. The stock closed up 1.35% at HK$52.5.

After market close on the same day, AB&B BIO-TECH released its interim results for the six months ended June 30, 2025. The report showed that the group's revenue for the period reached RMB 71.123 million, representing a substantial increase of 919.25% compared to the same period last year. Gross profit stood at RMB 60.781 million, while R&D expenses continued to increase significantly, reaching RMB 98.848 million.

AB&B BIO-TECH is a China-based vaccine company dedicated to the research, development, manufacturing and commercialization of innovative vaccines and traditional vaccines using new technological approaches. The company's product pipeline covers two core products: a quadrivalent influenza virus subunit vaccine and a freeze-dried human rabies vaccine in development, along with 11 other vaccines under research. All of the company's vaccine products and products in development are currently or expected to be classified as Category II vaccines in China.

Additionally, AB&B BIO-TECH has established three comprehensive vaccine development support platforms: the company's genetic engineering and protein expression and purification platform, mRNA vaccine research platform, and adjuvant development and production platform. As of June 30, 2025, the company has successfully obtained nine IND approvals for its investigational vaccines from the National Medical Products Administration.